Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Paris - Delayed Quote EUR

Poxel S.A. (POXEL.PA)

Compare
0.2140
-0.0235
(-9.89%)
At close: April 4 at 5:35:12 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for POXEL.PA

Recent News: POXEL.PA

View More
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment

Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment
Business Wire 6 days ago
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
Business Wire 16 days ago
Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook

Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook
Business Wire last month
Poxel Announces Results of its Combined General Meeting Held on February 11, 2025

Poxel Announces Results of its Combined General Meeting Held on February 11, 2025
Business Wire last month
Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast

Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast
Business Wire 2 months ago
Poxel Announces its Financial Calendar for 2025

Poxel Announces its Financial Calendar for 2025
Business Wire 2 months ago
Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025
Business Wire 2 months ago
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment
Business Wire 2 months ago
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan
Business Wire 2 months ago
Availability of Poxel’s 2024 Half-Year Financial Report

Availability of Poxel’s 2024 Half-Year Financial Report
Business Wire 3 months ago
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook

Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook
Business Wire 3 months ago
View More

Related Tickers

ALTHX.PA Theranexus Société Anonyme
0.4300
-0.46%
 
ALBPS.PA Biophytis S.A.
0.2032
-0.88%
 
SIGHT.PA GenSight Biologics S.A.
0.2040
-9.93%
 
ALTME.PA TME Pharma N.V.
0.0691
-2.68%
 
ADOC.PA Adocia SA
3.3900
-9.60%
 
OSE.PA OSE Immunotherapeutics SA
5.16
-6.35%
 
IPH.PA Innate Pharma S.A.
1.7240
-5.27%
 
5NRA.MU Nanobiotix SA
3.1800
-3.05%
 
3MM.MU Advicenne SA
1.5760
+3.01%
 
C4X.F Valerio Therapeutics Société anonyme
0.0648
+8.91%